Scientific Advisory Board.

Dr. Ronald Postuma is an internationally renowned clinician-scientist specializing in Parkinson’s disease and related neurodegenerative disorders. As Director of the Division of Neurology at McGill University and the Montreal Neurological Institute, his research has significantly advanced global understanding of prodromal Parkinson’s, sleep-related biomarkers, and disease progression. Dr. Postuma has led pivotal studies on REM sleep behavior disorder (RBD) as a predictor of neurodegeneration and has authored key clinical criteria for early diagnosis. With extensive experience in translational research and clinical trial design, he also advises pharmaceutical and biotechnology companies developing disease-modifying therapies for Parkinson’s disease. His work bridges academic excellence with industry innovation, accelerating the translation of discoveries into patient impact.

‍

Prof. Dr. Charlotte Teunissen is a globally recognized expert in neurodegenerative disease biomarkers, with a particular focus on Alzheimer’s and Parkinson’s disease. As Head of the Neurochemistry Laboratory at Amsterdam UMC, she leads pioneering research on fluid biomarkers for early diagnosis, prognosis, and monitoring of therapeutic responses. Her work covers the full spectrum of biomarker development, from discovery to clinical validation and implementation. Prof. Teunissen oversees one of the world’s largest dementia biobanks and chairs multiple international consortia. She also receives and advises on grants from the Michael J. Fox Foundation. Her contributions have been instrumental in advancing ultrasensitive proteomic technologies and in vitro diagnostics that support precision medicine in neurodegeneration.

Prof. Dr. Nicola Pavese is a distinguished neurologist and clinical neuroscientist specializing in Parkinson’s disease and other neurodegenerative disorders. He holds professorships at both Newcastle University and Aarhus University, where he contributes to cutting-edge research in neuroimaging and translational neuroscience. At Aarhus University Hospital, Prof. Pavese is affiliated with the Department of Nuclear Medicine, where his research focuses on PET-MRI imaging to study synaptic density in Parkinson’s disease and to identify biomarkers for prodromal stages of neurodegeneration. He has authored over 350 scientific publications and oversees numerous academic and industry-sponsored clinical trials.

Dr. Margherita Fabbri is a neurologist at Toulouse University Hospital and a leading researcher in the field of Parkinson’s disease and atypical parkinsonian syndromes. She is actively involved in the French NS-Park Network, contributing to national research initiatives aimed at improving diagnosis, treatment, and quality of life for patients with parkinsonian syndromes. Her clinical and academic work encompasses advanced therapies, pharmacoepidemiology, and multidisciplinary care approaches, with over 130 peer-reviewed publications to her name. Dr. Fabbri also plays a key role in European collaborative studies and clinical trials focused on disease progression and therapeutic innovation.

Prof. Dr. Günter Höglinger is the Director of the Department of Neurology at LMU Klinikum Munich and a leading expert on neurodegenerative disorders, particularly Parkinson’s disease and related movement disorders. His research bridges clinical and basic neuroscience, focusing on the pathological mechanisms underlying alpha-synuclein and tau protein aggregation. Prof. Höglinger has led numerous international research consortia and clinical trials aimed at developing innovative diagnostic tools and therapies for Parkinson’s syndromes. He also serves as the founding chair of the German Society for Parkinson’s and Movement Disorders and played a key role in establishing the Parkinson Foundation.